ArticleNeuroimage. Reports2026
DTI-ALPS as a marker of glymphatic function: Review of the literature findings, methodology, and interpretation.
Article in Neuroimage. Reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glymphatic system (GS) describes how the brain clears toxins and metabolic waste. Accumulation of these elements can contribute to onset and severity of brain disorders, so the importance of measuring the GS is vital to understanding how neurological disease may occur and potentially lead to developing preventative treatments. A simple technique referred to as Diffusion Tensor Image Analysis ALong the Perivascular Space (DTI-ALPS) was developed as a non-invasive MRI marker of GS functioning. However, various aspects of its measurement and putative interpretation have led to critiques of the technique and discussion focused upon whether it is truly a measure of GS. We located 393 DTI-ALPS articles with an exponential growth during the past few years. The most studied conditions where this technique has been employed was neurodegenerative diseases, followed by many other conditions such as sleep disorders, epilepsy, stroke, and mood disturbances. While most studies found a significant association with DTI-ALPS and their cohorts, there has been significant discussion related to the interpretation of the DTI-ALPS index and the mechanisms underlying changes in this value. The majority of studies found significant associations between DTI-ALPS and disease severity, although issues related to differences in methodologies are important to consider. Finally, the methods employed to generate the DTI-ALPS measurements as well as the variation in these approaches are summarized. DTI-ALPS is mathematically governed by radial diffusivity asymmetry and axonal geometry, and it serves as a highly sensitive but non-specific marker of white matter microstructural damage and neuroinflammation. Retrospectively applicable and highly reproducible, DTI-ALPS offers substantial translational potential for low-cost, large-scale clinical screening and longitudinal trial stratification when paired with other biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.